The P-gp expels a wide variety of drugs from tumor cells, leading to a decrease in intracellular drug concentration and the MDR phenotype; thus, it limits the therapeutic effect, resulting in low bioavailability [52]. This evidence concerns the gene PGP and neoplasm.